Details of the Drug

General Information of Drug (ID: DM4MSLY)

Drug Name
ZN-c3
Indication
Disease Entry ICD 11 Status REF
Uterine serous carcinoma 2C72.1 Phase 2 [1]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DRQN21

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Uterine serous carcinoma
ICD Disease Classification 2C72.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Wee1-like protein kinase (WEE1) DTT WEE1 7.06E-07 1.06 4.21
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04814108) A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
3 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
4 Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur J Med Chem. 2009 Apr;44(4):1383-95.